USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1
- 5 September 2023
- journal article
- research article
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 30 (10) , 2249-2264
Abstract
The abnormal upregulation of programmed death ligand-1 (PD-L1) on tumor cells impedes T-cell mediated cytotoxicity through PD-1 engagement, and further exploring the mechanisms regulation of PD-L1 in cancers may enhance the clinical efficacy of PD-L1 blockade. Here, using single-guide RNAs (sgRNAs) screening system, we identify ubiquitin-specific processing protease 2 (USP2) as a novel regulator of PD-L1 stabilization for tumor immune evasion. USP2 directly interacts with and increases PD-L1 abundance in colorectal and prostate cancer cells. Our results show that Thr288, Arg292 and Asp293 at USP2 control its binding to PD-L1 through deconjugating the K48-linked polyubiquitination at lysine 270 of PD-L1. Depletion of USP2 causes endoplasmic reticulum (ER)-associated degradation of PD-L1, thus attenuates PD-L1/PD-1 interaction and sensitizes cancer cells to T cell-mediated killing. Meanwhile, USP2 ablation-induced PD-L1 clearance enhances antitumor immunity in mice via increasing CD8+ T cells infiltration and reducing immunosuppressive infiltration of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), whereas PD-L1 overexpression reverses the tumor growth suppression by USP2 silencing. USP2-depletion combination with anti-PD-1 also exhibits a synergistic anti-tumor effect. Furthermore, analysis of clinical tissue samples indicates that USP2 is positively associated with PD-L1 expression in cancer. Collectively, our data reveal a crucial role of USP2 for controlling PD-L1 stabilization in tumor cells, and highlight USP2 as a potential therapeutic target for cancer immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (82273960, 81973366, 82273854 and 82003792)
This publication has 52 references indexed in Scilit:
- Regulatory T cells in cancer immunotherapyCurrent Opinion in Immunology, 2014
- Immune Modulation in Cancer with AntibodiesAnnual Review of Medicine, 2014
- Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domainsCell Communication and Signaling, 2014
- The Ubiquitin CodeAnnual Review of Biochemistry, 2012
- MYC Is Activated by USP2a-Mediated Modulation of MicroRNAs in Prostate CancerCancer Discovery, 2012
- Mice Lacking the USP2 Deubiquitinating Enzyme Have Severe Male Subfertility Associated with Defects in Fertilization and Sperm MotilityBiology of Reproduction, 2011
- Stringent requirement for HRD1, SEL1L, and OS-9/XTP3-B for disposal of ERAD-LS substratesJournal of Cell Biology, 2010
- Granzymes in cancer and immunityCell Death & Differentiation, 2010
- One step at a time: endoplasmic reticulum-associated degradationNature Reviews Molecular Cell Biology, 2008
- OS-9 and GRP94 deliver mutant α1-antitrypsin to the Hrd1–SEL1L ubiquitin ligase complex for ERADNature Cell Biology, 2008